BPH诊疗指南

患者出现肾积水的发生率随着残

余尿量的增 加而明显上升

18

。

6

．症状评分

症状评分在预测

BPH

临床进展也有一定的价值

6

，

15

，

17

，

I-PSS>7

分的< /p>

BPH

患

者发生急性尿潴留的风险是

I-PSS<7

分者的

4

< br>倍

6

。对于无急性尿潴留病史的

BPH

患者，储尿

期症状评分及总的症状评分均有助于预测

BPH

患者接受手术治疗的风险

15

。

此外，长期高血压

(

尤其是高舒张压

)19

、前列腺移 行带体积及移行带指数

20

－

21

也可能与

BPH

的临床进展有关。尽管研究表明有多种因素可以预测

BPH

的临 床进展．但目前得到多数

研究支持、预测

BPH

临床进展的指标是年龄、

PSA

及前列腺体积等。随着对

BPH

临床进展性

的危险因素研究的日益完善，将使筛选出具有临床进展风险的

BPH

患者成为可能，以便适时进

行临床干预。

参考文献

1.

Jacobsen

SJ.

Jacobson

DJ.

Girman

CJ,

Roberts

RO,

Rhodes

T

.

Guess

HA,

Lieber

MM.

Treatment

for

benign

prostalic

hyperplasia

among

community

dwelling

men:

the

Olmsted

County study of urinary symptoms and health status. J Urot,1999,162 : 1301-1306

2.

McConnell

JD,

Bruskewitz

R,

Walsh

P

,

Andriole

G,

Lieber

M,

Holtgrewe

sen

P

,

Roehrborn CG, Nickel JC, Wang DZ, Taylor AM. Waldstreicher J. The effect of finasteride on the

risk of acute urinary retention mad the need for surgical treatment among men with benign

prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med,

1998,338: 557-563

3. McConnell JD, Roehrborn CG, Bautista OM. Andriole GL Jr

, Dixon CM. Kusek JW

, Lepor H,

McVary KT

, Nyberg LM Jr

, Clarke HS, Crawford ED, Diokno A, Foley JP

, Foster HE, Jacobs SC,

Kaplan SA, Kreder KJ, Lieber MM. Lucia MS, Miller GJ, Menon M, Milam

DF

,

Ramsdell

JW

,

Schenkman

NS,

Slawin

KM,

Smith

JA.

The

long-term

effect

of

doxazosin,

finasteride, and combination therapy on the clinical progression of benign prostatie hyperplasia.

N Engl J Med, 2003,349: 2387-2398

4. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield

S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J. Serum prostate-

specific antigen concentration is a powerful predictor of acute urinary retention and need for

surgery in men with clinical benign prostatic hyperplasia. PLESS Study

Group. Urology, 1999,53: 473-480

5.

Jiménez-Cruz

F

.

Identifying

patients

with

lower

urinary

tract

symptoms/benign

prostatic

hyperplasia at risk for progression. Eur Urol,2003,2: 6-12

6. Jacobsen SI, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T

, Guess HA, Lieber MM. Natural

history of prostatism: risk factors for acute urinary retention. J Urol, 1997,158: 481-487

7. Roehrborn CG,Boyle P

, Nickel JC. PSA is a significant predictor of objective parameters in

men at risk of BPH progression. J Urol, 2003,169: 364-365

8. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and

risk

factors

for

acute

urinary

retention:

the

health

professionals

follow

up

study.

J

Urol,

1999,162: 376-382

9.

Roehrborn

CG,Boyle

P

,Gould

AL,

Waldstreicher

J.

Serum

prostate-specific

antigen

as

a

predictor

of

prostate

volume

in

men

with

benign

prostatic

hyperplasia.

Urol-ogy,1999,53:

581-589

10. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF

,

Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P

, Roy J, Andriole G, Resnick M,

Waldstreicher J. Serum prostate specific antigen is a strong predictor of future prostate growth

in men with benign prostatic hy-perplasia

LESS study. J Urol,2000,163: 13-20

11. Wright EJ, Fang J, Metter EJ, Partin AW

, Landis P

, Chan DW

, Carter HB. Prostate specific

antigen

predicts

the

long-term

risk

of

prostate

enlargement:

resuhs

from

the

Baltimore

longitudinal study of aging. J Urol,2002,167: 2484-2488

12. Roehrborn CG, Boyle P

, Bergner D, Gray T

, Gittelman M. Shown T

. Melman A, Bracken RB,

deVere

White

R,

Taylor

A,

Wang

D,

Waldstreicher

J.

Serum

prostate

specific

antigen

and

prostate volume predict long term changes in symptoms and flow rate: results of a four year

randomized trial comparing finasteride versus placebo. Urology. 1999,54: 662-669

13. Marberger MJ. Andersen JT

, Nickel JC, Malice MP

, Gabriel M, Pappas F

, Meehan A, Stoner E,

Waldst-reicher J. Prostate Volume and serum prostate-specific antigen as predictors of acute

urinary retention. Combined experience from three large multinational placebo-controlled trials.

Eur Urol,2000,38: 563-568

14.

Roehrborn

CG,

Malice

M,

Cook

TJ,

Girman

CJ.

Clinical

predictors

of

spontaneous

acute

urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled

placebo groups of several large clinical trials. Urology,2001,58: 210-216

15.

Roehrborn

CG,

McConnell

JD,

Saltzman

B,

Bergner

D,

Gray

T

,

Narayan

P

,

Cook

TJ,

Johnson-Levonas

AO,

Quezada

WA,

Waldstreicher

J.

Storage

(Irritative)

and

Voiding

(Obstructive) Symptoms as Predictors of Benigh Prostatic Hyperplasia Progression and Related

Outcomes. Eur Urol.2002,42: 1-6

16

．朱绍兴，陈仕平，李启镛，林震，郑松，翁明高．血清前 列腺特异性抗原和移行带指数与

良性前列腺增生急性尿潴留的关系．中华实验外科杂志，

2003

，

20:1113

17. Lowe FC. Batista J, Berges R, Chartier-Kastler E. Conti G, Desgrandchamps F

. Dreikorn K,

Oleary M, Perez M. Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H.

Risk

factors

for

disease

progression

in

patients

with

lower

urinary

tract

symptoms/benign

prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer and

Prostatic Diseases, 2005, Jun 14, [Epub ahead of print]

18

．王寅，黄长海，高广智，辛永春，林哲放，李晓东，潘明军．前列腺增生症病人待机处理

期间剩余尿量测定的临床意义．中华泌尿外科杂志，

2000

，

21:621

—

623 < /p>

19

．郭利君，张祥华，李培军，那彦群．良性前列腺增生与原发 性高血压的相关性研究．中华

外科杂志，

2005

，

43:108

－

111

20

．张光银，陈山，刘跃新，毕维琪，郑宇鹏，乔庐东，张波 ．前列腺体积参数与良性前列腺

增生临床参数的相关性研究．中华泌尿外科杂志，

2002

，

23:474

—

476

21

．魏东，苏洪学， 伍建业，许进，万奔，那彦群．前列腺移行区体积和移行区指数在诊断良

性前列腺增生中 的作用．临床泌尿外科杂志，

2002

，

l7:653

—

655